Pulling SEC filings + quote and writing the call…

CVRx, Inc.
Next earnings Aug 3, 2026 (after close) · consensus $-0.53 EPS, $15.9M rev
Last earnings -12.3% on 2026-05-11
Revenue grew 10.4% YoY; but unprofitable (net margin -94.1%).
Revenue (FY2025) $56.7M · FY2025
CVRx, Inc. shows $56.7M in FY2025 revenue (+10.4% YoY), a -94.1% net margin, and -135.6% ROE.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $13.0M | $22.5M | $39.3M | $51.3M | $56.7M |
| Gross profit | $9.40M | $17.5M | $33.0M | $43.0M | $48.3M |
| Operating income | -$26.0M | -$42.5M | -$43.1M | -$59.5M | -$51.3M |
| Net income | -$43.1M | -$41.4M | -$41.2M | -$60.0M | -$53.3M |
| Diluted EPS | -$4.16 | -$2.02 | -$1.99 | -$2.65 | -$2.04 |
| Net margin | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001235912, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:26:16 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2026-06-01 | Nielsen Kirk G. Director | Award | 8.72K | |
| 2026-06-01 | Jain Mudit K. Director | Award | 8.72K | |
| 2026-06-01 | SLATTERY JOSEPH P Director | Award | 8.72K | |
| 2026-06-01 | Hill, Mitch C. Director | Award | 8.72K | |
| 2026-06-01 | Ballinger Kevin J. Director | Award | 8.72K | |
| 2026-06-01 | SHADAN MARTHA Director | Award | 8.72K | |
| 2026-06-01 | DALE MICHAEL D Director | Award | 29.0K | |
| 2026-03-02 | Adamson Philip B. Chief Medical Officer | Sell | 1.26K @ $7.90 | $9.97K |
| 2026-02-27 | Adamson Philip B. Chief Medical Officer | Award | 41.0K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1044 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.